Utech Secures Initial Order of 800,000 COVID-19 Prevention Products from US CVS and Amazon

[Asia Economy Reporter Hyunseok Yoo] Bio company Salvacion, which has signed a joint business contract with U-Tech, has begun supplying the initial batch of the novel coronavirus (COVID-19) 100% inactivation bacterial preventive agent (hereinafter ‘COVIXYL-G’).

U-Tech announced on the 4th that Salvacion, the bio company with which it signed a joint business contract, has completed the first order of ‘COVIXYL-G’ and has started domestic production of 800,000 units, part of the initial batch, aiming for release within the year.

A Salvacion official stated, “We decided to produce part of the initial batch in Korea to secure overseas suppliers, fearing that demand could not be met by production solely in the United States once global supply of ‘COVIXYL-G’ is in full swing.”

U-Tech holds manufacturing and production rights for the Asia region.

The finished product is scheduled to be first released this month at the United States’ largest pharmacy chains Walgreens, CVS, and Amazon, with an expected retail price of $19.99.

Previously, ‘COVIXYL-G’ was proven to inactivate 100% of the COVID-19 virus as well as sterilize 99.99% of various respiratory disease-related bacteria, received approval from the U.S. FDA, and filed PCT patents in major countries worldwide.

A Salvacion official explained, “Starting with the initial delivery of ‘COVIXYL-G,’ global supply including the United States is expected to expand significantly,” adding, “We are accelerating strategic partnerships with global companies.”

Meanwhile, U-Tech has been restructuring its business portfolio this year by divesting underperforming divisions and shifting towards the healthcare sector, including mask manufacturing and distribution and development of virus inactivation preventive agents amid the COVID-19 pandemic.